Roche and Ionis Pharmaceuticals will share the interim results with health regulators to accelerate the drug's path to market. The trial continues through Week 105 to evaluate long-term kidney function. This result marks the second positive Phase 3 readout in 24 hours for Ionis, which licensed the treatment to Roche and is eligible for tiered royalties and regulatory milestones.
Wednesday, October 21, 2026
Story
Roche and Ionis Hit Primary Phase 3 Goal for Kidney Drug
Business28 days ago
Sefaxersen produced a statistically significant and clinically meaningful reduction in proteinuria at Week 37 of an interim Phase 3 study involving 459 patients. The therapy, an antisense drug targeting complement factor B, is administered once monthly and demonstrated a safety profile consistent with prior research for the treatment of IgA nephropathy.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.